Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Danaher Corporation (DHR) vs Xpeng Inc - ADR (XPEV) Price & Performance

Danaher CorporationTrade
Xpeng Inc - ADRTrade

Price performance (Past 24H)

Key statistics

Danaher Corporation vs Xpeng Inc - ADR — how do they compare? Danaher Corporation trades at $220.09 (market cap $152.87B), while Xpeng Inc - ADR trades at $9.88 (market cap $9.16B). The key difference: Danaher Corporation is far larger — about 16.7× Xpeng Inc - ADR's market cap, and Danaher Corporation pays a 0.74% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Xpeng Inc - ADR for 80 Days on average.

DHRXPEV
Market Cap
$152.87B$9.16B
Volume
5,228,6985,030,325
Sector
HealthConsumer Cyclical
52-Week High
$242.05$28.07
52-Week Low
$161.91$9.25
Typical Hold Time
69 Days80 Days
Enterprise Value
$175.08B$11.09B
Dividend Yield
0.74%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Danaher Corporation

Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.

The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.

Xpeng Inc - ADR

XPeng (XPEV) trades at $9.92, up 3.55% today, but remains in a bearish technical trend. The company shows mixed fundamentals with strong revenue growth to $76.72B in 2025 but persistent net losses. Recent Q2 2026 earnings missed expectations, though vehicle deliveries surged 65% quarter-over-quarter. Analyst consensus remains bullish with a $17.55 price target, representing 77% upside potential from current levels.

XPeng presents a high-risk, high-reward opportunity with significant growth potential in EVs and robotics, but profitability challenges and competitive pressures create substantial risk. The stock's current valuation at 0.81 P/S appears attractive if the company can achieve sustainable profitability, but investors face execution risk amid China's competitive EV market and global expansion challenges.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DHR
3% Buy97% Sell
Avg holding period · 69 Days
XPEV
28% Buy72% Sell
Avg holding period · 80 Days

Top news

Latest headlines on both assets

About Danaher Corporation

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.

Read more on DHR →

About Xpeng Inc - ADR

Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.

Read more on XPEV →